-
公开(公告)号：US20130071409A1
公开(公告)日：2013-03-21
申请号：US13576249
申请日：2011-02-04
申请人： James L. Riley , Chrystal Paulos , Carl H. June , Bruce Levine
发明人： James L. Riley , Chrystal Paulos , Carl H. June , Bruce Levine
IPC分类号： A61K35/26 , C12N5/10 , A61P29/00 , A61K39/395 , A61P37/02 , C12N5/078 , C12N5/0783
CPC分类号： C12N5/0637 , A61K35/17 , A61K2039/5158 , A61K2039/57 , C12N5/0636 , C12N2501/2301 , C12N2501/2302 , C12N2501/2306 , C12N2501/2321 , C12N2501/2323 , C12N2501/51 , C12N2501/515 , C12N2501/599
摘要： The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
-
2.发明授权公开(公告)号：US12071648B2
公开(公告)日：2024-08-27
申请号：US16650492
申请日：2018-09-25
申请人： GENOSKIN
CPC分类号： C12Q1/025 , C12N5/0629 , C12N2501/15 , C12N2501/2301 , C12N2501/2302 , C12N2501/2323 , C12N2501/51 , C12N2501/515
摘要： Disclosed is an ex-vivo model of inflamed skin, an in-vitro method for obtaining the same and uses thereof for screening anti-inflammatory compounds. The method includes injecting, into the dermis of a healthy skin biopsy previously taken from a mammal, a composition including an effective amount for activating dermal resident T cells of an anti-CD3 antibody and an anti-CD28 antibody; and b) incubating the injected skin biopsy obtained in step a) in the presence of a composition including an effective amount, for obtaining the polarization of the T cells activated in step a) into LTh1 and/or LTh17 and the synthesis of inflammation markers, of at least one mixture of IL-1β, IL-23, and TGF-β.
-
3.发明授权ICOS critically regulates the expansion and function of inflammatory human Th17 cells 有权ICOS严格控制炎症性人Th17细胞的扩增和功能公开(公告)号：US09133436B2
公开(公告)日：2015-09-15
申请号：US13576249
申请日：2011-02-04
申请人： James L. Riley , Chrystal Paulos , Carl H. June , Bruce Levine
发明人： James L. Riley , Chrystal Paulos , Carl H. June , Bruce Levine
IPC分类号： C12N5/10 , A61K38/19 , A61K39/395 , C12N5/0783 , A61K35/17 , A61K39/00
CPC分类号： C12N5/0637 , A61K35/17 , A61K2039/5158 , A61K2039/57 , C12N5/0636 , C12N2501/2301 , C12N2501/2302 , C12N2501/2306 , C12N2501/2321 , C12N2501/2323 , C12N2501/51 , C12N2501/515 , C12N2501/599
摘要： The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
摘要翻译： 本发明包括用于产生和扩大治疗性Th17细胞的组合物和方法。 本发明包括使T细胞与包含能够向T细胞提供主要激活信号的第一药剂和能够在Th-17偏振剂存在下在T细胞上活化ICOS的第二药剂的组合物接触。
-
公开(公告)号：US20080279813A1
公开(公告)日：2008-11-13
申请号：US11815420
申请日：2006-02-02
IPC分类号： A61K45/00 , C12Q1/04 , G01N33/53 , A61K38/21 , A61K39/00 , A61P37/00 , A61K31/70 , A61K35/12 , A61K39/395
CPC分类号： C12N5/0637 , A61K35/17 , A61K38/1793 , A61K38/20 , A61K38/2033 , A61K38/208 , A61K38/217 , A61K39/001 , A61K2039/5158 , C07K16/244 , C07K2317/76 , C12N2501/2302 , C12N2501/2304 , C12N2501/2305 , C12N2501/2312 , C12N2501/2323 , C12N2501/24 , G01N33/505 , G01N33/5094 , G01N2333/52 , G01N2333/54 , G01N2333/5406 , G01N2333/5409 , G01N2333/5434 , G01N2333/55 , G01N2333/57 , G01N2333/70514 , G01N2333/70596 , G01N2333/715 , G01N2800/245 , A61K2300/00
摘要： The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.
摘要翻译： 本发明涉及一种评估受试者是否包含已被激活到特异性抗原的CD4 +，CD25 + T细胞的方法。 该方法包括以下步骤：从受试者获得包含CD4 +，CD25 + T细胞的淋巴细胞样品，培养淋巴细胞样品的至少一部分，以促进已激活的CD4 +，CD25 + T细胞与特异性抗原的区别 从未激活到特异性抗原的那些CD4 +，CD25 + T细胞，然后确定是否存在活化于特异性抗原的CD4 +，CD25 + T细胞存在于样品中。 本发明还涉及在体外培养已被激活到特定抗原的CD4 +，CD25 + T细胞的方法和使用已经在体外培养的CD4 +，CD25 + T细胞增加受试者耐受性的方法。
-
公开(公告)号：US20240122986A1
公开(公告)日：2024-04-18
申请号：US18543191
申请日：2023-12-18
IPC分类号： A61K35/17 , A61K9/00 , A61K35/26 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/24 , C07K16/28 , C07K16/30 , C12N5/0783
CPC分类号： A61K35/17 , A61K9/0019 , A61K35/26 , A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/249 , C07K16/2896 , C07K16/30 , C12N5/0636 , C12N5/0638 , C07K2317/55 , C07K2317/76 , C12N2501/15 , C12N2501/2301 , C12N2501/2306 , C12N2501/2312 , C12N2501/2323 , C12N2501/599
摘要： The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
-
公开(公告)号：US11883430B2
公开(公告)日：2024-01-30
申请号：US16347743
申请日：2017-11-08
IPC分类号： A61K35/17 , A61P35/00 , A61K35/26 , C07K16/24 , C12N5/0783 , A61K45/06 , A61K9/00 , C07K16/28 , C07K16/30 , A61K39/395
CPC分类号： A61K35/17 , A61K9/0019 , A61K35/26 , A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/249 , C07K16/2896 , C07K16/30 , C12N5/0636 , C12N5/0638 , C07K2317/55 , C07K2317/76 , C12N2501/15 , C12N2501/2301 , C12N2501/2306 , C12N2501/2312 , C12N2501/2323 , C12N2501/599 , A61K39/39558 , A61K2300/00
摘要： The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
-
公开(公告)号：US20140370038A1
公开(公告)日：2014-12-18
申请号：US14312117
申请日：2014-06-23
IPC分类号： C12N5/0783 , A61K38/20 , A61K38/21 , A61K35/14
CPC分类号： C12N5/0637 , A61K35/17 , A61K38/1793 , A61K38/20 , A61K38/2033 , A61K38/208 , A61K38/217 , A61K39/001 , A61K2039/5158 , C07K16/244 , C07K2317/76 , C12N2501/2302 , C12N2501/2304 , C12N2501/2305 , C12N2501/2312 , C12N2501/2323 , C12N2501/24 , G01N33/505 , G01N33/5094 , G01N2333/52 , G01N2333/54 , G01N2333/5406 , G01N2333/5409 , G01N2333/5434 , G01N2333/55 , G01N2333/57 , G01N2333/70514 , G01N2333/70596 , G01N2333/715 , G01N2800/245 , A61K2300/00
摘要： The invention relates to a method of assessing whether a subject includes CD4+,CD25+ T cells that have been activated to a specific antigen. The method includes the steps of obtaining from the subject a sample of lymphocytes including CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote, distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.
摘要翻译： 本发明涉及一种评估受试者是否包括已被激活到特定抗原的CD4 +，CD25 + T细胞的方法。 该方法包括以下步骤：从受试者获得包括CD4 +，CD25 + T细胞的淋巴细胞样品，培养淋巴细胞样品的至少一部分，以促进已被激活的CD4 +，CD25 + T细胞与特异性 来自没有被激活到特定抗原的那些CD4 +，CD25 + T细胞的抗原，然后确定在特定抗原中活化的CD4 +，CD25 + T细胞是否存在于样品中。 本发明还涉及在体外培养已被激活到特定抗原的CD4 +，CD25 + T细胞的方法和使用已经在体外培养的CD4 +，CD25 + T细胞增加受试者耐受性的方法。
-
8.发明公开公开(公告)号：US20240165162A1
公开(公告)日：2024-05-23
申请号：US18550484
申请日：2022-04-07
发明人： Katy REZVANI , Elizabeth SHPALL , David MARIN COSTA , Rafet BASAR
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C07K16/28 , C12N5/0783
CPC分类号： A61K35/17 , A61P35/00 , C07K16/28 , C12N5/0646 , A61K2039/505 , C12N2501/2302 , C12N2501/2304 , C12N2501/2307 , C12N2501/2312 , C12N2501/2315 , C12N2501/2318 , C12N2501/2321 , C12N2501/2323
摘要： Embodiments of the disclosure concern methods and compositions related to preparation and use of combinatorial immunotherapies. In specific embodiments, compositions comprising NK cells prepared in a particular manner also include certain antibodies. These compositions are utilized for treatment, such as for cancer treatment. In particular embodiments, the compositions include complexes of the NK cells and the antibodies in which the antibody is bound to the NK cells and may also bind to another antigen, such as on a cancer cell.
-
公开(公告)号：US20240108689A1
公开(公告)日：2024-04-04
申请号：US18273579
申请日：2022-01-21
申请人： The Brigham and Women's Hospital, Inc. , The Broad Institute, Inc. , The General Hospital Corporation , The Regents of the University of California
发明人： Vijay K. Kuchroo , Ramnik Xavier , Mathias Pawlak , David DeTomaso , Nir Yosef
IPC分类号： A61K38/17 , A61P37/02 , C12N5/0783 , C12N9/22
CPC分类号： A61K38/177 , A61P37/02 , C12N5/0636 , C12N9/22 , C12N2310/20 , C12N2501/2312 , C12N2501/2321 , C12N2501/2323 , C12N2503/02 , C12N2510/00
摘要： The subject matter disclosed herein is generally directed to pathogenic Th1 cells whose phenotype is dependent on IL-23R signaling. Th1 cell specific therapeutic targets and gene programs are disclosed herein. In particular, inhibition of CD160 reduces Th1 cell pathogenicity.
-
10.发明公开公开(公告)号：US20230399615A1
公开(公告)日：2023-12-14
申请号：US18117255
申请日：2023-03-03
发明人： James L. Riley , Chrystal Paulos , Carl H. June , Bruce L. Levine
IPC分类号： C12N5/0783 , A61K35/17
CPC分类号： C12N5/0637 , A61K35/17 , C12N5/0636 , C12N2501/2323 , A61K2039/5158
摘要： The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.018 秒)
